Riccardo Autorino, MD, PhD, FEBU, summarizes the American Urological Association (AUA), the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) guidelines on clinically localized prostate cancer. Specifically, he highlights recommendations on shared decision making, risk stratification to dictate the therapy, care options, active surveillance, and directions for future research.
Read More
Riccardo Autorino MD, PhD, FEBU, discusses the decline in using cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) due to the shift toward targeted therapy in urological practice. He explains the rationale behind CN, its drawbacks, and individual scenarios in which it could provide a benefit, as opposed to targeted therapy and nephron-sparing surgery (NSS). Furthermore, he presents the current therapeutic algorithm for patient selection in these treatment options.
Read More
Riccardo Autorino, MD, PhD, FEBU, defines oligometastatic prostate cancer, a newly-explored concept in the urological community. He discusses whether or not radical prostatectomy offers significant oncological benefits that outweigh the risk of complications and negative impacts on urinary function and QOL outcomes for patients in this stage.
Read More
Riccardo Autorino, MD, PhD, FEBU, summarizes the current EAU, AUA, and ASCO recommendations regarding partial and radical nephrectomies, the effect robotic surgery has had in this clinical area, and whether or not nephron sparing surgery is a beneficial and safe method for the management of large renal masses.
Read More
Riccardo Autorino, MD, PhD, FEBU, reviews the assets and limitations of the robotic systems currently available for clinical urological applications, especially the da Vinci system. He describes the global scene of emerging systems, such as the REVO-I and the avatera-System, as well as multiple systems under development.
Read More